BiotechTube

Investigational Treatment + Active comparator

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Mar 5, 2015 → Jan 27, 2016

NCT ID
NCT02404389

About Investigational Treatment + Active comparator

Investigational Treatment + Active comparator is a phase 2 stage product being developed by Novartis for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02404389. Target conditions include Actinic Keratosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02404389Phase 2Completed

Competing Products

20 competing products in Actinic Keratosis

See all competitors
ProductCompanyStageHype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
33
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
76
FluorouracilSanofiPhase 1/2
40
fluorouracil cream 0.5%SanofiApproved
84
Imiquimod + DiclofenacViatrisApproved
82
Imiquimod 5 % CreamViatrisPhase 2
49
ImiquimodViatrisPre-clinical
20
Aldara (Imiquimod)ViatrisPhase 3
74
Imiquimod + DiclofenacViatrisApproved
82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
62
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
72
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
47
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
80
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
72
Tirbanibulin 2.5 mg ointmentAlmirallApproved
80

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85